In the context of oncogenes and clinical characteristics, patients in the high-risk subtype were frequently accompanied by mutations of NRAS, KARS, and TP53. Of note, AML with RAS mutation was associated with VEN-resistance and monocytic phenotype (27, 81). The gene discussed is KARS1; the disease is acute myeloid leukemia.